https://www.selleckchem.com/products/GDC-0449.html
95; 95% CI, 0.84-1.07; P=0.382) and the risk of hemorrhagic brain stroke (RR, 1.00; 95% CI, 0.66-1.51; P=0.999) between patients treated with PCSK9 inhibitors and controls. PCSK9 inhibitors did not significantly increase the incidence of neurocognitive adverse events (RR, 1.02; 95% CI, 0.81-1.29; P=0.85). Moreover, subgroup analysis showed no difference in cognitive function disorder risks among different PCSK9 inhibitors and treatment times. PCSK9 inhibitors significantly reduced the risk of total brain stroke and ischemic brain strok
Like
Comment
Share
